Agomelatine may improve REM sleep behavior disorder symptoms

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 732-734

  Bonakis, Anastasios ^a,b   Economou, Nicholas Tiberio ^a   Papageorgiou, Sokratis G ^a   Vagiakis, Emmanuil ^b   Nanas, Serafeim ^b   Paparrigopoulos, Thomas ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; DONEPEZIL; LEVODOPA; PRAMIPEXOLE; QUETIAPINE; TRIAZOLAM;

ABSENCE OF SIDE EFFECTS; APNEA HYPOPNEA INDEX; COMORBIDITY; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE SEVERITY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; FOLLOW UP; HUMAN; LATENT PERIOD; LEG MOVEMENT; LETTER; MICROANGIOPATHY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP; SCORING SYSTEM; SEDATION; SIDE EFFECT;

ACETAMIDES; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; MALE; REM SLEEP BEHAVIOR DISORDER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865865860     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31826866f8     Document Type: Letter

References (11)

1. Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15-54.
2. Trotti LM. REM sleep behavior disorder in older individuals. Epidemiology, pathophysiology and management. Drugs Aging. 2010;27(6):457-470.
3. Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19:591-596.
4. Gagnon, JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67:742-747.
5. San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry. 2008;6:396-402.
6. Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009;18:1533-1540.
7. Iber C, Ancoli-Israel S, Chesson AL, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications.Westchester, IL: American Academy of Sleep Medicine; 2007.
8. Montplaisir J, Gagnon JF, Fantini ML, et al. Polysomnograhic diagnosis of idiopathic REM sleep behavior disorder. Mov Disord. 2010;25:2044-2051.
9. Fantini ML, Corona A, Clerici S, et al. Aggressive dream content without daytime aggressiveness in REM sleep behavior disorder. Neurology. 2005;65:1010-1015.
10. Braun AR, Balkin TJ, Wesenten NJ, et al. Regional cerebral flow throughout the sleep-wake cycle. An H2 15O PET study. Brain. 1997;120:1173-1197.
11. Kunz D, Bes F. Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations. Neuropsychobiology. 1997;36(4):211-214.